Nature as a remarkable chemist: a personal story of the discovery and development of Taxol.

Mansukh C. Wani, Susan Band Horwitz

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The development of a new anticancer drug with a novel structure and unique mechanism of action is an important event, especially when the drug plays a clear role in improving the outcome for cancer patients. No drug fits this description better than Taxol. However, during the early phases of its development, there was little interest in the drug, particularly in the medical community. The story of Taxol is long and fascinating, and includes many examples in which the drug could have been dropped, resulting in its antitumor activity never being available to patients. It was 21 years between the original landmark paper on the isolation and structural determination of Taxol and its approval in 1992 by the FDA for its use in the treatment of ovarian cancer.

Original languageEnglish (US)
Pages (from-to)482-487
Number of pages6
JournalAnti-Cancer Drugs
Volume25
Issue number5
StatePublished - 2014

Fingerprint

Paclitaxel
Pharmaceutical Preparations
Ovarian Neoplasms
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Nature as a remarkable chemist : a personal story of the discovery and development of Taxol. / Wani, Mansukh C.; Band Horwitz, Susan.

In: Anti-Cancer Drugs, Vol. 25, No. 5, 2014, p. 482-487.

Research output: Contribution to journalArticle

@article{1300f7ea0de1430493e64f8887f8d7d5,
title = "Nature as a remarkable chemist: a personal story of the discovery and development of Taxol.",
abstract = "The development of a new anticancer drug with a novel structure and unique mechanism of action is an important event, especially when the drug plays a clear role in improving the outcome for cancer patients. No drug fits this description better than Taxol. However, during the early phases of its development, there was little interest in the drug, particularly in the medical community. The story of Taxol is long and fascinating, and includes many examples in which the drug could have been dropped, resulting in its antitumor activity never being available to patients. It was 21 years between the original landmark paper on the isolation and structural determination of Taxol and its approval in 1992 by the FDA for its use in the treatment of ovarian cancer.",
author = "Wani, {Mansukh C.} and {Band Horwitz}, Susan",
year = "2014",
language = "English (US)",
volume = "25",
pages = "482--487",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Nature as a remarkable chemist

T2 - a personal story of the discovery and development of Taxol.

AU - Wani, Mansukh C.

AU - Band Horwitz, Susan

PY - 2014

Y1 - 2014

N2 - The development of a new anticancer drug with a novel structure and unique mechanism of action is an important event, especially when the drug plays a clear role in improving the outcome for cancer patients. No drug fits this description better than Taxol. However, during the early phases of its development, there was little interest in the drug, particularly in the medical community. The story of Taxol is long and fascinating, and includes many examples in which the drug could have been dropped, resulting in its antitumor activity never being available to patients. It was 21 years between the original landmark paper on the isolation and structural determination of Taxol and its approval in 1992 by the FDA for its use in the treatment of ovarian cancer.

AB - The development of a new anticancer drug with a novel structure and unique mechanism of action is an important event, especially when the drug plays a clear role in improving the outcome for cancer patients. No drug fits this description better than Taxol. However, during the early phases of its development, there was little interest in the drug, particularly in the medical community. The story of Taxol is long and fascinating, and includes many examples in which the drug could have been dropped, resulting in its antitumor activity never being available to patients. It was 21 years between the original landmark paper on the isolation and structural determination of Taxol and its approval in 1992 by the FDA for its use in the treatment of ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=84908375133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908375133&partnerID=8YFLogxK

M3 - Article

C2 - 24413390

AN - SCOPUS:84908375133

VL - 25

SP - 482

EP - 487

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 5

ER -